Wave Life Sciences Ltd
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
WVE$3.41-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss)
(In thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Revenue | $(7,676) | $49,214 | $24,554 | $84,249 |
| Operating expenses: | ||||
| Research and development | 41,197 | 31,642 | 115,037 | 95,935 |
| General and administrative | 15,042 | 13,128 | 42,887 | 37,628 |
| Total operating expenses | 56,239 | 44,770 | 157,924 | 133,563 |
| Income (loss) from operations | (63,915) | 4,444 | (133,370) | (49,314) |
| Other income, net: | ||||
| Dividend income and interest income | 1,798 | 1,960 | 6,425 | 6,084 |
| Other income, net | 337 | 171 | 684 | 1,296 |
| Total other income, net | 2,135 | 2,131 | 7,109 | 7,380 |
| Income (loss) before income taxes | (61,780) | 6,575 | (126,261) | (41,934) |
| Income tax benefit (provision) | — | 677 | — | 677 |
| Net income (loss) | $(61,780) | $7,252 | $(126,261) | $(41,257) |
| Less: net income attributable to participating securities | $— | $(257) | $— | $— |
| Net income (loss) attributable to ordinary shareholders, basic and diluted | $(61,780) | $6,995 | $(126,261) | $(41,257) |
| Net income (loss) per share attributable to ordinary shareholders—basic | $(0.47) | $0.07 | $(0.97) | $(0.39) |
| Weighted-average ordinary shares used in computing net income (loss) per share attributable to ordinary shareholders—basic | 132,563,467 | 106,025,063 | 130,470,603 | 104,529,266 |
| Net income (loss) per share attributable to ordinary shareholders—diluted | $(0.47) | $0.07 | $(0.97) | $(0.39) |
| Weighted-average ordinary shares used in computing net income (loss) per share attributable to ordinary shareholders—diluted | 132,563,467 | 106,975,231 | 130,470,603 | 104,529,266 |
| Other comprehensive income (loss): | ||||
| Net income (loss) | $(61,780) | $7,252 | $(126,261) | $(41,257) |
| Foreign currency translation | 120 | (32) | (35) | (153) |
| Comprehensive income (loss) | $(61,660) | $7,220 | $(126,296) | $(41,410) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.